Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 16/20 | 1.00 |
| ▸ | DPP7 | Q9UHL4 | 15/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 14/20 | 1.00 |
| ▸ | PREP | P48147 | 11/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4635388 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP7DPP9PREP | |
| SCHEMBL4888159 | 0.91 | DPP4 (0.84) | DPP4DPP8DPP7DPP9PREP | |
| SCHEMBL4888165 | 0.91 | DPP4 (0.84) | DPP4DPP8DPP7DPP9PREP | |
| SCHEMBL4635012 | 0.90 | DPP4 (1.00) | DPP4DPP8DPP7DPP9PREP | |
| SCHEMBL4900350 | 0.90 | DPP4 (1.00) | DPP4DPP8DPP7DPP9PREP | |
| SCHEMBL4635437 | 0.89 | DPP4 (1.00) | DPP4DPP8DPP7DPP9PREP | |
| SCHEMBL4635441 | 0.89 | DPP4 (1.00) | DPP4DPP8DPP7DPP9PREP | |
| SCHEMBL4897238 | 0.88 | DPP4 (1.00) | DPP4DPP8DPP7DPP9PREP | |
| SCHEMBL4897021 | 0.88 | DPP4 (0.81) | DPP4DPP8DPP7DPP9PREP | |
| SCHEMBL4892865 | 0.87 | DPP4 (1.00) | DPP4DPP8DPP7DPP9PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-04 | — | — | US | claimed |
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-04 | — | — | US | disclosed |
| EP-1931633-A2 | DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007029086-A2 | DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | DPP4, DPP3, DPP8 | DPP4 1/4885DPP8 3/4885DPP7 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.